Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  Disease Landscape and Forecast Insights

Alzheimer’s Disease – Unmet Need – Unmet Need – Early Alzheimer’s Disease (US/EU)

Login to access report north_east
Contact sales account_box

Eisai / Biogen’s lecanemab (Leqembi) and Eli Lilly’s donanemab (Kisunla) are modestly effective in reducing cognitive and functional decline, require frequent IV infusions, and carry ARIA-related safety risks. Emerging DMTs with near-term launch potential (e.g., subcutaneous lecanemab, Eli Lilly’s remternetug, Roche’s trontinemab, Novo Nordisk’s semaglutide) may deliver greater biomarker and/or clinical efficacy, lower ARIA risk, or improved delivery profiles. This report examines the influence of a key clinical (e.g., reduction of cognitive and functional decline, plaque clearance, ARIA risk) and nonclinical (i.e., out-of-pocket cost) attributes on neurologists’ prescribing decisions and assesses the key opportunities for differentiation from Leqembi, Kisunla, and procognitive symptomatics in the early AD market.

QUESTIONS ANSWERED

  • How important is a therapy’s effect on cognition, function, or biomarker outcomes in neurologists’ selection of a therapy for early AD?
  • How do neurologists rate Leqembi, Kisunla, and procognitive symptomatics on their overall performance in the treatment of early AD and on key individual attributes?
  • Based on conjoint analysis and TPP simulation, what trade-offs among efficacy, safety, treatment duration, and other factors are neurologists willing to make when considering a hypothetical DMT for early AD?

PRODUCT DESCRIPTION

Unmet Need offers insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities, enabling you to:

  • Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians’ weightings and analysis of stated vs. derived importance.
  • Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.
  • Analyze market scenarios for different target product profiles using the TPP Simulator

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 61 U.S. and 32 European neurologists fielded in December 2023

Key companies: AbbVie, Biogen, Eisai, Eli Lilly, Roche

Key drugs: Leqembi, Kisunla, donepezil, galantamine, Namzaric, rivastigmine patch

Table of contents

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Psoriatic Arthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Psoriatic Arthritis (US)
Treatment of psoriatic arthritis (PsA) typically begins with conventional DMARDs, such as methotrexate, and progresses to more-potent biologics and/or targeted oral therapies as needed. The U.S…
north_east
Report
Small-Cell Lung Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)
The treatment landscape for small-cell lung cancer (SCLC) has seen significant advances in the past few years. Previously, chemotherapy and radiotherapy were the predominant treatments, but…
north_east
Report
Atopic Dermatitis / Atopic Eczema – Access & Reimbursement – Access & Reimbursement – Atopic Dermatitis (US)
The treatment landscape for AD in the United States is evolving rapidly. Since 2017, the FDA has approved multiple agents, including systemic and topical JAK inhibitors, nonsteroidal topical…
north_east
Report
Renal Anemia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Renal Anemia (US)
Renal anemia is a common complication of chronic kidney disease (CKD). When kidneys are diseased or impaired, they fail to generate enough EPO, causing renal anemia. The primary goal of renal…
north_east
Report
Biosimilars – Current Treatment – Endocrinology
Eli Lilly / Boehringer Ingelheim’s Abasaglar / Basaglar was the first biosimilar / follow-on insulin glargine to launch in Europe and the United States, followed by Sanofi’s Admelog / Insulin…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east